Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Other Non-Current Assets for 8 consecutive years, with $968000.0 as the latest value for Q1 2026.

  • Quarterly Other Non-Current Assets rose 7.44% to $968000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $968000.0 through Feb 2026, up 7.44% year-over-year, with the annual reading at $968000.0 for FY2025, 69.36% down from the prior year.
  • Other Non-Current Assets for Q1 2026 was $968000.0 at Nurix Therapeutics, roughly flat from $968000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $7.4 million in Q3 2025, with the low at $901000.0 in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $1.4 million, with a median of $901000.0 recorded in 2022.
  • Peak annual rise in Other Non-Current Assets hit 718.53% in 2025, while the deepest fall reached 69.36% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $901000.0 in 2022, then changed by 0.0% to $901000.0 in 2023, then soared by 250.61% to $3.2 million in 2024, then plummeted by 69.36% to $968000.0 in 2025, then changed by 0.0% to $968000.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $968000.0, $968000.0, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.